Obagi Medical (OMPI) Tops Q2 View; Guides Q3 Below the Street
More News related to OMPI
- Thomas Weisel Starts Obagi Medical (OMPI) at Market Weight
- Brean Murray Initiates Coverage on Obagi Medical Products (OMPI) with Buy
- Obagi Medical Products Reports First Quarter 2009 Financial Results
- Obagi Medical Products (OMPI) Discontinues Distribution in the Pharmacy Channel
- Obagi Medical Products (OMPI) Says Condition & Enhance System Improves Results of Intense Pulsed Light Treatments
Obagi Medical Products, Inc. (NASDAQ: OMPI) reports Q2 EPS of $0.20, 1 cent better than the analyst estimate of $0.19. Revenues for the quarter were $27.8 million, versus the consensus of $27.20 million.
Sees Q3 revs in the range of $25.5-$27.5 million, versus the consensus of $28.37 million, and EPS of $0.13-$0.15, versus the Street estimate of $0.22.
Obagi Medical Products, Inc., a specialty pharmaceutical company, develops and markets skincare products in the United States and internationally.
Related Categories
EarningsGuidance
Stocks Mentioned
-0.18Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
